Dasatinib + Quercetin (D+Q) for Neurodegeneration

Dasatinib + Quercetin (D+Q) for Neurodegeneration

Introduction

Dasatinib + Quercetin (D+Q) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox"> [@xu2018]
| Category | Value | [@bussian2018]
|---------|-------| [@musi2018]
| Combination | Dasatinib + Quercetin | [@zhang2023]
| Abbreviation | D+Q | [@ogrodnik2019]
| Class | Senolytic agents | [@chaib2022]
| Mechanism | Bcl-2 family inhibition | [@kirkland2023]
| Status | Phase I/II clinical trials | [@justice2024]
| Administration | Oral, intermittent | [@hickson2023]
</div>

Overview

Dasatinib + Quercetin (D+Q) for Neurodegeneration

Introduction

Dasatinib + Quercetin (D+Q) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox"> [@xu2018]
| Category | Value | [@bussian2018]
|---------|-------| [@musi2018]
| Combination | Dasatinib + Quercetin | [@zhang2023]
| Abbreviation | D+Q | [@ogrodnik2019]
| Class | Senolytic agents | [@chaib2022]
| Mechanism | Bcl-2 family inhibition | [@kirkland2023]
| Status | Phase I/II clinical trials | [@justice2024]
| Administration | Oral, intermittent | [@hickson2023]
</div>

Overview

Dasatinib + Quercetin (D+Q) is the most extensively studied senolytic drug combination, consisting of the tyrosine kinase inhibitor dasatinib and the flavonoid quercetin["@kirkland2018"]. This combination selectively eliminates senescent cells that accumulate with age and contribute to chronic inflammation and tissue dysfunction, making it a promising therapeutic approach for neurodegenerative diseases.

The rationale for combining these two drugs comes from their complementary mechanisms: dasatinib targets Bcl-2 family anti-apoptotic proteins while quercetin inhibits multiple pro-survival pathways, together effectively inducing [apoptosis](/entities/apoptosis) in senescent cells while sparing normal cells.

Pharmacology

Individual Drug Properties

| Property | Dasatinib | Quercetin |
|----------|-----------|-----------|
| Class | Tyrosine kinase inhibitor | Flavonoid |
| Primary target | Bcr-Abl, Src kinases | PI3K, Bcl-2, [mTOR](/mechanisms/mtor-signaling-pathway) |
| FDA approval | Yes (leukemia) | No (dietary supplement) |
| Brain penetration | Moderate | Moderate |
| Half-life | 3-5 hours | 11-16 hours |

Combination Mechanism

The D+Q combination works synergistically:

• Inhibits Bcl-2, Bcl-xL, Bcl-w survival proteins
• Blocks Src family kinases
• Induces apoptosis in senescent cells

• PI3K/Akt pathway inhibition
• Bcl-2 family modulation
• Senolytic activity through multiple targets

• Enhanced senolytic activity vs either alone
• Broader target coverage
• Reduced required doses

Clinical Evidence

Completed Trials

| Trial | Phase | Condition | Status | Key Finding |
|-------|-------|-----------|--------|-------------|
| NCT02848131 | I | COPD | Completed | Safety established |
| NCT03415087 | I | Alzheimer's | Completed | Safety, biomarker signals |
| NCT03675724 | I | IPF | Completed | Reduced senescent cells |

Ongoing Trials

| Trial | Phase | Condition | Status |
|-------|-------|-----------|--------|
| NCT04685590 | I/II | Parkinson's | Recruiting |
| NCT04833517 | II | Cognitive decline | Planning |

Biomarker Results

From completed trials:

• Reduced senescent cell burden in blood
• Decreased SASP factors (IL-6, IL-8, TNF-α)
• Improved physical function in elderly

Preclinical Evidence

Alzheimer's Disease

| Model | Outcome | Mechanism |
|-------|---------|-----------|
| 3xTg-AD mice | Reduced cognitive decline | Clearance of senescent [microglia](/cell-types/microglia-neuroinflammation) |
| Tauopathy model | Less [tau](/proteins/tau) pathology | Senolytic effect |
| Aged mice | Improved cognition | Reduced neuroinflammation |

Parkinson's Disease

| Model | Outcome | Mechanism |
|-------|---------|-----------|
| MPTP model | Protected DA [neurons](/entities/neurons) | Senescent glial clearance |
| [α-synuclein](/proteins/alpha-synuclein) mice | Reduced aggregation | [Autophagy](/entities/autophagy) enhancement |
| Aged mice | Improved motor function | Multi-target effects |

ALS and Other Conditions

• ALS models: Delayed disease onset, extended survival
• Stroke models: Reduced infarct size
• Traumatic brain injury: Improved recovery

Dosing Protocol

Intermittent Dosing

The original senolytic protocol uses intermittent dosing:

| Parameter | Value |
|-----------|-------|
| Dasatinib dose | 100 mg |
| Quercetin dose | 1000 mg |
| Frequency | 3 days/week or 2 consecutive days/week |
| Cycle length | Continuous |

Alternative Protocols

| Protocol | Dasatinib | Quercetin | Schedule |
|----------|-----------|-----------|----------|
| Original | 100mg | 1000mg | 3 days/week |
| Low-dose | 50mg | 500mg | Daily |
| Pulsed | 100mg | 1000mg | 2 days/week |

Safety Profile

Adverse Events

| Event | Frequency | Severity |
|-------|-----------|----------|
| Nausea | 20-30% | Mild-moderate |
| Fatigue | 15-20% | Mild |
| Fluid retention | 10-15% | Manageable |
| Headache | 10% | Mild |

Special Considerations

• Dasatinib: FDA-approved for leukemia, well-characterized safety
• Quercetin: Generally recognized as safe (GRAS)
• Combination: No unexpected toxicities

Drug Interactions

• CYP3A4 substrates (dasatinib is substrate)
• Anticoagulants
• Antiplatelet agents

Challenges and Future Directions

Current Limitations

Next-Generation Approaches

See Also

• [Senolytic Therapies for Neurodegeneration](/therapeutics/senolytic-therapies-neurodegeneration-4007)
• [Senolytics and Senotherapeutics](/therapeutics/senolytics-senotherapeutics-neurodegeneration-1676)
• [Cellular Senescence in Aging](/mechanisms/cellular-senescence-aging)
• [Neuroinflammation Pathways](/mechanisms/neuroinflammation-pathways)

Background

The study of Dasatinib + Quercetin (D+Q) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Emerging Research

Biomarker Development

Key biomarkers for D+Q response:

• p16INK4a: Senescent cell marker in blood
• SASP factors: IL-6, IL-8, PAI-1
• Senescent cells: FACS analysis
• Inflammatory markers: CRP, TNF-α

Next-Generation Senolytics

| Agent | Advantage | Stage |
|-------|-----------|-------|
| Fisetin | Natural, well-tolerated | Phase II |
| Navitoclax | Potent Bcl-2 inhibitor | Phase I |
| AMPK activators | Multiple benefits | Preclinical |

Conclusion

The D+Q combination represents the most clinically advanced senolytic therapy. While challenges remain regarding brain penetration and optimal dosing, the strong preclinical data and growing clinical evidence support continued development for neurodegenerative diseases. The ongoing Phase I/II trials in Parkinson's disease will provide crucial efficacy data.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;